Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | FSCN1 | Q16658 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | UBE2N | P61088 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315711 | 0.81 | SCD (0.63) | SCDSMN1; SMN2MAPK1FSCN1LMNA | |
| SCHEMBL3421426 | 0.81 | SCD (0.59) | SCDSMN1; SMN2MAPK1FSCN1LMNA | |
| SCHEMBL2312640 | 0.79 | SCD (0.63) | SCDSMN1; SMN2MAPK1FSCN1LMNA | |
| SCHEMBL2317199 | 0.78 | SCD (1.00) | SCDSMN1; SMN2MAPK1FSCN1 | |
| SCHEMBL14048851 | 0.74 | SCD (0.60) | SCDSMN1; SMN2MAPK1FSCN1HTT | |
| SCHEMBL2312076 | 0.74 | SCD (0.76) | SCDSMN1; SMN2MAPK1FSCN1 | |
| SCHEMBL23555556 | 0.73 | TP53 (0.57) | SCDSMN1; SMN2MAPK1LMNATP53 | |
| SCHEMBL2317598 | 0.73 | SCD (0.76) | SCDSMN1; SMN2MAPK1FSCN1LMNA | |
| SCHEMBL2312070 | 0.73 | SCD (0.76) | SCDSMN1; SMN2MAPK1FSCN1 | |
| SCHEMBL3087107 | 0.72 | SCD (0.63) | SCDSMN1; SMN2MAPK1FSCN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-04-23 | — | — | US | disclosed |
| WO-2008127615-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV THERAPEUTICS INC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | SCD 1/4885SMN1; SMN2 3593/4885MAPK1 2689/4885 |
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | SCD 1/4885SMN1; SMN2 3593/4885MAPK1 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.